Cassava Sciences, Inc. Gains 42.03%

Cassava Sciences, Inc. (SAVA:NASDAQ) soared at $10.07, representing a gain of 42%. The stock appeared on our News Catalysts scanner on Wed 16 Sep 20 at 02:29 PM in the 'BIOTECH' category. From Thu 03 Sep 20, the stock recorded 66.67% Up Days and 60.00% Green Days

The stock spiked on Mon 11 May 20 at $10.18 with a volume of 1M+.

About Cassava Sciences, Inc. (SAVA:NASDAQ)

Pain Therapeutics Inc is a biopharmaceutical company. It develops proprietary drugs that offer improvements to patients and healthcare professionals. The company generally focuses on the drug development efforts on disorders of the nervous system, such as chronic pain. Pain Therapeutics operates in the single operating segment. Pain Therapeutics's drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The company's other product includes FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use.